Dihydroergocristine surveillance in chronic cerebrovascular disease

F. G. Mailland, E. Felici, P. M. Piatti

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

A dihydroergocristine surveillance was carried out in 9,702 patients with chronic cerebrovascular disease given 6 mg daily for 40 days. A total of 788 Italian general practitioners took part in the study. From 75 to 85% of the patients had improvement or recovery. Blood pressure was reduced in hypertensive patients while it was unaffected in the normo- and hypotensive individuals. 4.8% of patients reported side effects but only 42 out of 9,702 patients dropped out, while in the others the side effects spontaneously disappeared during the treatment. Most adverse reactions were gastrointestinal (3.34%). More women than men complained of nausea, the difference being statistically significant. Other side effects concerned the central nervous system, skin and soft tissues, autonomic nervous system and cardiovascular system. Postural hypotension was reported in only 4 cases. Data suggest safety of dihydroergocristine in monitored use.

Original languageEnglish
Pages (from-to)997-1003
Number of pages7
JournalCurrent Therapeutic Research
Volume33
Issue number6 I
Publication statusPublished - 1983

Fingerprint

Dihydroergocristine
Cerebrovascular Disorders
Chronic Disease
Orthostatic Hypotension
Autonomic Nervous System
Cardiovascular System
General Practitioners
Nausea
Central Nervous System
Blood Pressure
Safety
Skin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Dihydroergocristine surveillance in chronic cerebrovascular disease. / Mailland, F. G.; Felici, E.; Piatti, P. M.

In: Current Therapeutic Research, Vol. 33, No. 6 I, 1983, p. 997-1003.

Research output: Contribution to journalArticle

Mailland, F. G. ; Felici, E. ; Piatti, P. M. / Dihydroergocristine surveillance in chronic cerebrovascular disease. In: Current Therapeutic Research. 1983 ; Vol. 33, No. 6 I. pp. 997-1003.
@article{8eadd42543204fab885f90ab7f9df3ad,
title = "Dihydroergocristine surveillance in chronic cerebrovascular disease",
abstract = "A dihydroergocristine surveillance was carried out in 9,702 patients with chronic cerebrovascular disease given 6 mg daily for 40 days. A total of 788 Italian general practitioners took part in the study. From 75 to 85{\%} of the patients had improvement or recovery. Blood pressure was reduced in hypertensive patients while it was unaffected in the normo- and hypotensive individuals. 4.8{\%} of patients reported side effects but only 42 out of 9,702 patients dropped out, while in the others the side effects spontaneously disappeared during the treatment. Most adverse reactions were gastrointestinal (3.34{\%}). More women than men complained of nausea, the difference being statistically significant. Other side effects concerned the central nervous system, skin and soft tissues, autonomic nervous system and cardiovascular system. Postural hypotension was reported in only 4 cases. Data suggest safety of dihydroergocristine in monitored use.",
author = "Mailland, {F. G.} and E. Felici and Piatti, {P. M.}",
year = "1983",
language = "English",
volume = "33",
pages = "997--1003",
journal = "Current Therapeutic Research - Clinical and Experimental",
issn = "0011-393X",
publisher = "Excerpta Medica",
number = "6 I",

}

TY - JOUR

T1 - Dihydroergocristine surveillance in chronic cerebrovascular disease

AU - Mailland, F. G.

AU - Felici, E.

AU - Piatti, P. M.

PY - 1983

Y1 - 1983

N2 - A dihydroergocristine surveillance was carried out in 9,702 patients with chronic cerebrovascular disease given 6 mg daily for 40 days. A total of 788 Italian general practitioners took part in the study. From 75 to 85% of the patients had improvement or recovery. Blood pressure was reduced in hypertensive patients while it was unaffected in the normo- and hypotensive individuals. 4.8% of patients reported side effects but only 42 out of 9,702 patients dropped out, while in the others the side effects spontaneously disappeared during the treatment. Most adverse reactions were gastrointestinal (3.34%). More women than men complained of nausea, the difference being statistically significant. Other side effects concerned the central nervous system, skin and soft tissues, autonomic nervous system and cardiovascular system. Postural hypotension was reported in only 4 cases. Data suggest safety of dihydroergocristine in monitored use.

AB - A dihydroergocristine surveillance was carried out in 9,702 patients with chronic cerebrovascular disease given 6 mg daily for 40 days. A total of 788 Italian general practitioners took part in the study. From 75 to 85% of the patients had improvement or recovery. Blood pressure was reduced in hypertensive patients while it was unaffected in the normo- and hypotensive individuals. 4.8% of patients reported side effects but only 42 out of 9,702 patients dropped out, while in the others the side effects spontaneously disappeared during the treatment. Most adverse reactions were gastrointestinal (3.34%). More women than men complained of nausea, the difference being statistically significant. Other side effects concerned the central nervous system, skin and soft tissues, autonomic nervous system and cardiovascular system. Postural hypotension was reported in only 4 cases. Data suggest safety of dihydroergocristine in monitored use.

UR - http://www.scopus.com/inward/record.url?scp=0020529502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020529502&partnerID=8YFLogxK

M3 - Article

VL - 33

SP - 997

EP - 1003

JO - Current Therapeutic Research - Clinical and Experimental

JF - Current Therapeutic Research - Clinical and Experimental

SN - 0011-393X

IS - 6 I

ER -